Nasdaq16d
QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology
(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind ...
Business Wire17d
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent ...
Seeking Alpha22d
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company ...
Business Wire1mon
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
VENLO, The Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the official opening of a new data center in Melbourne ...
Frontiers1y
Transcriptional time course after rotator cuff repair in 6 month old female rabbits
In brief, the tissue was immersed in buffer RLT and disrupted by bead in the QIAGEN TissueLyser II, (QIAGEN, Germantown, MD) before being transferred to the Qiacube for RNA extraction. Samples were ...
Frontiers2y
A Leukocyte Migration Assay Assists Understanding of Interleukin-1β-Induced Leukocyte Migration Into Preterm Mouse Uterus
United States), homogenized by TissueLyser II (QIAGEN, Hilden, Germany), and centrifuged at 4°C, 13,000 × g for 10 min to extract total protein. Maternal whole blood (1–2 ml) was collected via cardiac ...